5 Key Takeaways

• 1

  Nemolizumab reduced pruritus in 58.4% of patients with moderate to severe prurigo nodularis by week 16, compared to 16.7% in the placebo group.

• 2

  The OLYMPIA 1 trial included 286 adults with moderate to severe prurigo nodularis, randomized to receive nemolizumab or placebo.

• 3

  IGA success was achieved in 26.3% of nemolizumab-treated patients versus 7.3% in the placebo group at week 16.

• 4

  Significant improvements in sleep disturbance were observed, with 50.0% of nemolizumab recipients reporting at least a 4-point improvement.

• 5

  Adverse events occurred in 71.7% of nemolizumab-treated patients, with most being mild to moderate and resolving by the study's end.